Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Eli Lilly and Company: exclusive worldwide license (Apr 2012) to develop and commercialize NEREUS for all human uses
Indications
Prevention of vomiting induced by motion(Approved)
Prevention of vomiting in patients receiving GLP-1 receptor agonist therapies(Phase 3)
Gastroparesis(Stage not disclosed)
Atopic dermatitis(Stage not disclosed)
Catalysts
— None
Status note NDA approved Dec 2025; early commercial launch initiated May 2026 via direct-to-consumer web portal (nereus.us). FDA issued a final order refusing to approve the NDA for gastroparesis (petition for review filed Mar 2026); FDA placed a partial clinical hold on a 52-week open-label gastroparesis safety study (lawsuit filed Apr 2026).
Status note FDA approved in Q1 2026; launch expected in the second half of 2026. Protected by data exclusivity through February 20, 2031 and multiple patents.
HETLIOZ
Approved · Active
Aliases tasimelteon
Target MT1/MT2
Partnerships Bristol-Myers Squibb: license agreement (milestone met on Jan 2014 NDA approval)
Status note NDA approved Jan 2014 for Non-24. FDA issued a final order refusing to approve the sNDA for insomnia (petition for review filed Apr 2025).
Quimilza
Phase 3 · ActiveModality: IL-36R antagonist
Aliases imsidolimab
Target IL-36R
Partnerships AnaptysBio: exclusive global license (Jan 2025) for worldwide rights to develop, manufacture and commercialize Quimilza
Indications
Generalized pustular psoriasis (GPP)(Phase 3)
Catalysts
— None
Status note BLA under FDA review (PDUFA Dec 12, 2026); pivotal study results published in NEJM Apr 28, 2026. Orphan drug designation in Japan (MHLW, May 2026); positive EMA COMP opinion (Jul 2026).
Partnerships Novartis Pharma AG: settlement agreement; all US and Canadian rights in the Fanapt franchise transferred Dec 31, 2014; 3% royalty paid directly to Sanofi
Indications
Acute treatment of manic or mixed episodes associated with bipolar I disorder; schizophrenia(Approved)
Status note Marketed commercial product.
PONVORY
Approved · Active
Aliases ponesimod
Target S1P1
Indications
Relapsing forms of multiple sclerosis (adults)(Approved)
Status note Marketed commercial product.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (20 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.